 |
|
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(4):725-738. Published online 2022 Mar 14 DOI: https://doi.org/10.3350/cmh.2022.0015
|
|
Citations to this article as recorded by
 Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
Tzu-I Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen
Cancers.2023; 15(4): 1148. CrossRef Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Lei Miao, Giovanni Targher, Christopher D. Byrne, Luca Valenti, Xiaolong Qi, MingâHua Zheng
Portal Hypertension & Cirrhosis.2022; 1(1): 57. CrossRef The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy
Bo Yuan, Jichun Ma, Jing Wang, Jinyong Hao
Frontiers in Endocrinology.2022;[Epub] CrossRef
|